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Abstract
Background: Colorectal cancer (CRC) is the third most common cancer and the fourth most frequent cause of 
cancer death worldwide. Nonetheless, despite being a frequent cancer on which many epidemiological international 
studies have already been written, Portuguese epidemiological data are scarce and in particular there are very few 
specific data for Minho Region, which is traditionally recognized as a high incidence area. 
Aim: Characterize CRC patients treated at Braga Hospital. 
Methods: Data regarding clinical and preoperative diagnostic examinations, operative reports and histopathological 
and follow-up data was collected prospectively and stored in two Excel PC databases (colon and rectal cancer) and 
statistically analysed using the Statistical Package for the Social Sciences, version 19.0 (SPSS Inc., Chicago, Illinois, 
USA). All comparisons were examined for statistical significance using Pearson’s chi-square (χ2) test and Fisher’s 
exact test (when n<5), with the threshold for significance P values <0.05. Overall survival and Survival free disease 
were both assessed using the Kaplan-Meier method. 
Results: The study comprises 672 patients with histological diagnosis of CRC treated in Braga Hospital between 
2005 and 2009. It included 62.3% males and 37.7% females and most patients (60.5%) were between 61-80 years old. 
65.3% of the cases arose from colon cancer and 34.7% from rectal cancer. We observed that 94.8% of the patients 
had no previous history of colorectal polyps. 4.1% had a previous personal history of CRC and 7.7% of a different 
cancer. 9.7% had a positive CRC family history. Most patients (81.3%) were symptomatic at diagnosis, while 18.8% 
were detected by routine colonoscopies. Colon and rectal cancer from most patients was at IIA stage and IV stage 
respectively. Follow-up time ranged between 1 and 5 years and, during this period, 26.7% of colon cancer patients and 
25.3% of rectal cancer patients died from a colorectal cancer-related cause; also, 14.6% and 19.3% respectively had 
recurrence, mainly in the liver. 
Conclusion: This is the first study of a large cohort of CRC patients from the Minho Region in Northern Portugal. 
The large majority of the 672 cases were diagnosed because symptomatic and at an advanced stage, with a relatively 
poor prognosis. These findings emphasize the need to start a screening program and diagnose CRC at an early stage, 
thus increasing cure rates and improving resource management.
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Background 
Colorectal cancer (CRC) is the third most common cancer [1-3] and 
the fourth most frequent cause of cancer deaths [1-4]. Globally, CCR 
incidence varies widely, with higher rates in North America, Australia 
and Western Europe, and the lowest rates in developing countries 
[5], although, in recent years, increasing colorectal cancer rates have 
been reported in these countries [6]. According to the World Health 
Organization (WHO), CRC is one of the most prevalent diseases of the 
Western world [7] and the second most common cause of death from 
malignant disease in the Western countries [8,9]. 
In Europe, data from WHO and National Registries reveals that 
CRC is the second most common cancer, after lung cancer in males 
and breast cancer in females [10]. European countries rank highest in 
the global statistics, both in terms of incidence and mortality [10,11] 
but, over the past twenty-five years, mortality rates among Caucasians 
have steadily declined [12] and data from WHO between 1997 and 
2007 shows a decline in CRC mortality from 19.7 to 17.4/100,000 in 
men and 12.5 to 10.5/100,000 in women [13]. This recent decrease 
in CRC mortality rates in several European countries is likely due to 
improvements in early diagnosis and treatment, with a consequent 
higher survival from the disease [13]. 
In Portugal, data from the National Statistic Registry revealed 
that CRC is the second most common cancer, after lung cancer, with 
an incidence of 5000/year and one of the main causes of death by 
neoplastic disease [14]. In the North of Portugal, data from RORENO 
(North Regional Oncologic Registry) shows that, in 2005, CRC was the 
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second most prevalent cancer, followed by prostate cancer in males and 
breast cancer in females [15], and the third cause of death by neoplastic 
disease in men, preceded by lung and gastric cancer, and the second 
cause of death by neoplastic disease in women, after breast cancer [16]. 
Most CRC are sporadic cancers, without a colorectal cancer 
family history. The remaining arise in individuals with an inherited 
predisposition to the disease (at least 15%) and in individuals with well-
defined mendelian syndromes (almost 5%); in this setting, colorectal 
cancer risk is very high [14,17]. Since epidemiological data on CRC 
is scarce in Portugal, and no data exists about the Minho region, the 
authors carried out a descriptive study to characterize CRC patients 
treated at Braga Hospital, a city in the North of Portugal with an area of 
reference of 300,000 patients. 
Methods 
Data from 672 patients with CRC diagnosis treated in Braga, 
Northern Portugal, between January 1st 2005 and January 1st 2010 was 
used to describe the distribution of colorectal carcinoma. The data was 
collected prospectively and includes: clinical and preoperative diagnostic 
examinations, operative reports by the surgeons, histopathological and 
follow-up data. This data was organized in two Excel databases (colon 
and rectal cancer). 
Clinical and preoperative diagnostic examinations included: age, 
gender, clinical presentation, past oncologic history, tumour localization, 
histological type, macroscopic appearance and preoperative staging. 
Tumour localization was recorded and classified as right sided 
(caecum, ascending colon, hepatic flexure and transverse colon) or left 
sided (splenic flexure, descending colon, sigmoid colon) and rectum 
(between anal verge and 15 cm at rigid rectoscopy). Rectal cancer 
localization was subdivided as superior, middle and lower third (≤ 15 
and >10 cm; ≤ 10 and >5 cm and ≤ 5 cm from anal verge, respectively). 
Operative reports by surgeons, including presence of perforation, 
tumour mobility and type of surgery, were also collected. All patients 
received antibiotic and thrombosis prophylaxis and all operations were 
performed by or under supervision of senior surgeons. An emergency 
surgery was defined as a surgery performed for obstruction or perforation 
of the colon or rectum. The histopathological reports included: tumour 
extent (T), extent of spread to lymph nodes (N), presence of distant 
metastasis (M), tumour differentiation, resection margin involvement 
and lymphatic and blood vessel invasion. The level of positive lymph 
nodes was not described in all specimens. The histological type of CRC 
was determined by two experienced pathologists and tumour staging 
was graded according to TNM classification, sixth edition. 
All patients were followed up periodically and their outcomes were 
investigated and collected until July 2012. 
Ethics committee approval 
The study protocol was approved by the Ethics Committee of Braga 
Hospital. All patients provided written consent. 5.2 Statistical analysis 
All clinical, surgical and follow-up data was collected and stored 
in an Excel PC database and all data was analysed statistically using 
the Statistical Package for the Social Sciences, version 19.0 (SPSS Inc., 
Chicago, Illinois, USA). 
Overall survival (OS) was defined as time from disease diagnosis 
until death from any cause and Survival free disease (DFS) was defined 
as time from disease diagnosis until disease relapse; both were assessed 
using the Kaplan-Meier method. 
Results 
Patient history data 
The casuistic included 672 patients, 419 (62.4%) males and 253 
(37.6%) females; the age range of most patients (61%) was 61-80 years 
old, 20.4% (n=137) was 41-60 years old; 16.1% (n=108) was older than 
81 and 2.5% (n=17) was younger than 40 years old. Except for the group 
older than 81 years old, CRC incidence was more frequent in men (Table 
1). 94.8% (n=637) of the patients had no history of previous colorectal 
polyps; from the patients with polyps, 4.3% (n=29) were tubular, 0.4% 
(n=3) adenomatous, 0.3% (n=2) tubulovillous and 1 was non-classified. 
From overall patients, 4.1% (n=28) had a previous personal history 
of CRC and 7.7 % (n=52) had personal history of other cancer. 9.7% 
(n=65) had a positive CRC familial history. 
Most of patients, 81.3% (n=546), with CRC were symptomatic 
at diagnosis, the remainder 18.8% (n=126) were asymptomatic and 
detected by routine colonoscopies. Of the symptomatic patients, 82.11% 
(n=450) presented symptoms 6 months prior to colonoscopy and 14.6% 
(n=98) after 6 months. Among the 672 patients, 439 tumours (65.3%) 
arouse from colon and 233 (34.7%) from rectum. 
Colon cancer 
Symptoms: In symptomatic patients, 17.1% (n=75) presented 
digestive bleeding, followed by large bowel obstruction, 15% (n= 66). 
Other frequent symptoms observed were: change in bowel habits (8.9%), 
change in bowel habits with digestive bleeding (8.6%), constitutional 
symptoms (6.6%), change in bowel habits with abdominal pain (6.4%) 
and abdominal pain (4.8%) (Table 2). 
Localization: Most cancers were left-colon, 56.7% (n=249), mainly 
in the sigmoid colon.. Right-sided tumours comprised 27% (n=119) of 
the patients (Table 3). 
Diagnosis and staging: Diagnosis was made by total colonoscopy 
in 76.1% (n=334) of cases and rectosigmoidoscopy in 13% (n=57). In 
10.9% (n=48), diagnosis was made by other imagiological exams and 
patients did not have a preoperative colonoscopy. 
Most lesions (47.2%, n=207) were polypoid/vegetant cancers (Table 
3). In 19.1% (n=84) of patients, synchronous lesions were observed. 
Pre-operative colon biopsy revealed colon adenocarcinoma in 83.8% 
Age Males (%) Females (%) Total (%)
0-40 9 8 17 (2.5)
41-60 89 48 137 (20.4)
61-80 267 143 410 (61)
81+ 54 54 108 (16.1)
Table 1: Age and sex distribution of Colon and Rectal Cancer Cases.
Symptom n (%)
Digestive bleeding 75 (17.1)
Large bowel obstruction 66 (15.0)
Change in bowel habit 39 (8.9)
Digestive bleeding+changes in bowel habit 38 (8.6)
Constitutional symptoms 29 (6.6)
Abdominal pain+changes in bowel habit 28 (6.4)
Study (ascites; anemia, deep venous thrombosis, hepatic 
metastasis; occult blood losses, colonvesical fistula)
23 (5.2)
Abdominal pain 21 (4.8)
Parcial large bowel obtruction 13 (3.0)
Large bowel perfuration 8 (1.8)
Table 2: Summary of presentation symptoms and signs of Colon Cancer Cases.
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(n=368) of the patients; 3.9% (n=17) had dysplastic lesions, 0.4% (n=2) 
had mucinous adenocarcinoma and for the remainder 11.9% we did 
not have pre-operative information. 85.7% (n=376) of patients were 
staged by computerized axial tomography and most patients (79.1%; 
n=347) with colon cancer had a localized cancer at diagnosis. Most 
patients with disseminated disease had hepatic metastasis, followed by 
lymph node metastasis. 
Histological staging: Histological staging was determined by two 
experienced pathologists and tumour staging was graded according 
to TNM classification, sixth edition (American Joint Committee on 
Cancer). In the majority of patients (33.7%; n=142) colon cancer was 
stage IIA, followed by stage IIIB (22.5%; n=95) (Table 3). 
Macroscopic serosal involvement: Of the patients examined, 295 
(69.9%) presented macroscopic serosal involvement and 103 (24.4%) 
presented no macroscopic serosal involvement (Table 3). 
Tumour differentiation: Most patients, 172 (40.8%), presented 
a moderated-differentiated tumour, followed by well and poorly-
differentiated tumour (168 and 41 patients, respectively). 0.2% of the 
patients (1 patient) presented an undifferentiated tumour Vascular 
Invasion (Table 3). Although no specific marker of lymphatic or 
hematogenous vessels was used, we documented that 229 patients 
(54.2%) had venous vessel invasion and 166 (39.3%) had lymphatic 
vessels invasion. In 156 (36.9%) and 209 (49.5%) patients, respectively, 
no invasion was documented and for the remainder no information 
was mentioned (Table 3). 
Follow-up: A total of 137 patients (31.2%) died from all causes, 
27.8% (122 patients) had a colorectal cancer-related cause and the 
remaining 3.4% (15 patients) died in the post-operative period 
(mortality within 30 days of surgery). Follow-up time ranged between 
2 and 7 years; 14.6% (62 patients) had recurrence during follow-
up. Stage IIIB was the stage most frequently associated with tumour 
recurrence. Most metastasis occurred in liver, followed by lymph node 
and lung. Local recurrence occurred in nine cases. Most metastasis 
and recurrence was asymptomatic (79.0%; n=49), and 29.0% of them 
(n=18) presented an asymptomatic elevation of tumour markers. The 
remaining cases presented patients with abdominal pain (4.8%; n=3), 
abdominal mass (4.8%; n=3), intestinal obstruction (3.2%; n=2), bone 
pain (3.2%; n=2), supraclavicular mass (1.6%; n=1), enterocutaneous 
fistula (1.6%; n=1) and pathological fracture (1.6%; n=1). 
Rectal cancer 
Symptoms: Most rectal cancer patients (88.5%, n=206 patients) 
were symptomatic at diagnosis. 20% (n=47) presented digestive 
bleeding, followed by digestive bleeding with change in bowel habits, 
17.4% (n=41). Other frequent symptoms observed were: change in 
bowel habits (13.2%; n=31) and large bowel obstruction (4.7%; n=11) 
(Table 4). 
Localization: Of the 233 rectal cancers, most (50.6%, n=118) were 
localized in the middle third (Table 3). 
Diagnosis and staging: In rectal cancer patients, diagnosis was 
made by total colonoscopy in 79.8% (n=186) and rectosigmoidoscopy 
in 18.9% (n=44). In 1.3% of cases (n=3), it was impossible to perform 
an endoscopic exam (rectal stenosis). Most lesions (55.8%, n=130) 
were polypoid/vegetant cancers (Table 3). Synchronous lesions were 
observed in 10.3% (n=24) of the patients. 
Pre-operative biopsy revealed rectal adenocarcinoma in 91.4% 
(n=213) of the patients, invasive adenocarcinoma in 2.1% (n=5), 
adenomatous dysplastic lesions in 4.7% (n=11); villous lesions in 1.3% 
(n=3) and mucinous adenocarcinoma in one patient (0.4%). Of the 
233 patients, 27.0% (n=63) had synchronic metastasis at diagnosis, 
more frequently lymph node and hepatic metastasis. Pelvic magnetic 
resonance (MR) and rectal endoscopic ultrasound (EUS) were used 
in combination for local staging. After staging, 26% (61 patients) 
had indication for neoadjuvant therapy, 21% (49 patients) underwent 
chemotherapy and radiotherapy, and the remaining had not done 
neoadjuvant therapy due to comorbidities (2 patients) or underwent 
chemotherapy or radiotherapy alone due to specific contraindications. 
Characteristics Colon
n (%)
Rectum
n (%)
Localization
Caecum: 34 (7.7) Ascending 
colon: 33 (7.5) 
Hepatic flexure: 52 (11.8) 
Transverse colon: 20 ( 4.6) 
Splenic flexure: 28 (6.4) 
Descending colon: 16 (3.6) 
Sigmoid colon: 193 (44)
Rectosigmoid transition: 12 (2.7)
Proximal: 49 (21) 
Middle: 118 (50.6) 
Distal: 66 (28.3)
Macroscopic appearance
Polypoid/vegetant 
ulcerated Infiltrative 
Exofitic
Villous
No information
207 (47.2)
92 (21.0)
37 (8.4)
49 (11.2)
0 (0)
54 (12.3)
130 (55.8)
49 (21.0)
25 (10.7)
21 (9.0)
1 (0.4)
7 (3)
Histological Staging
Stage:
0
I 
IIA 
IIB 
IIIA 
IIIB 
IIIC 
IV
9 (2.1)
55 (13.0)
142 (33.7)
11 (2.6)
6 (1.4)
95 (22.5)
18 (4.3)
79 (18.7)
21 (10.3)
38 (18.7)
43 (21.2)
0 (0.0)
12 (5.9)
31 (15.3)
13 (6.4)
37 (18.2)
Serosal involvement
With
Without
No information
295 (69.9)
103 (24.4)
24 (5.7)
109 (53.7)
70 (34.5)
24 (11.8)
Tumour differentiation
Table 3: Summary of Clinical and Histopathological characteristic of Colon and 
Rectal Cancer Cases.
Symptom n (%)
Digestive bleeding 47 (20)
Digestive bleeding+change in bowel habit 41 (17.4)
Change in bowel habit 31 (13.2)
Large bowel obstruction 11 (4.7)
Incomplete stool evacuation sensation 11 (4.7)
Tenesmus 10 (4.2)
Tenesmus+Digestive bleeding 10 (4.2)
Digestive bleeding+constitutional symptoms 7 (3.0)
Abdominal pain 7 (3.0)
Constitutional symptoms 6 (2.6)
Abdominal pain+digestive bleeding 5 (2.1)
Tenesmus+changes in bowel habit+Digestive bleeding 5 (2.1)
Study (hepatic metastasis, pelvic mass) 4 (1.7)
Tenesmus+changes in bowel habit 4 (1.7)
Change in bowel habit+constitutional symptoms 3 (1.3)
Large bowel perfuration 2 (0.9)
Urgency 1 (0.4)
Anal pain 1 (0.4)
Table 4: Summary of presentation symptoms and signs of Rectal Cancer Cases.
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Histological staging: Post-operative histological staging was 
determined by two experienced pathologists and tumour staging was 
graded according to the TNM classification, sixth edition (American 
Joint Committee on Cancer). Most patients with rectal cancer were 
stage IIA (21.2%) and stage I (18.7%), followed by stage IV (18.2% 
patients). In 8 patients, post-operative histological stage was not 
determinate because the patients underwent surgery without resection 
(ex. derivative colostomy) (Table 3). 
Macroscopic serosal involvement: Of the patients examined, 109 
(53.7%) presented macroscopic serosal involvement and 70 (34.5%) 
presented no macroscopic serosal involvement (Table 3). 
Tumour differentiation: Most patients, 80 (39.4%), presented 
a moderated-differentiated tumour, followed by well and poorly-
differentiated tumour 73 (36.0%) and 9 (4.4%) patients, respectively). 
1.0% of the patients (2 patients) presented an undifferentiated tumour; 
for 40 patients, this data was not mentioned (Table 3). 
Vascular invasion: As previous mentioned, although no specific 
marker of lymphatic or hematogenous vessels was used, we documented 
that 113 (55.6%) patients had venous vessel invasion and 90 (44.3%) 
had lymphatic vessels invasion. In 59 (29.0%) and 81 (39.9%) patients, 
respectively, no invasion was documented and for the remainder no 
information was mentioned (Table 3). 
Follow-up: A total of 52 patients (22.3%) died from all causes, 28.0% 
(42 patients) had a colorectal cancer-related cause and the remaining 
4.3% (10 patients) died in the post-operative period (mortality within 
30 days of surgery). Follow-up time ranged from 2 to 7 years; 18.0% 
(42 patients) had recurrence during follow-up. Stage IV was the stage 
most often associated with tumour recurrence/progression. Most 
metastasis occurred in liver, followed by lymph node and lung. Local 
recurrence occurred in nine patients. Most patients with metastasis 
and recurrences (73.8%; n=31) were asymptomatic and 14.2% of them 
(n=6) presented an asymptomatic elevation of tumour markers. In the 
case of symptomatic patients, the most frequent symptoms were a rectal 
mass (9.5%; n=4) and intestinal obstruction (4.7%; (n=2)). 
CRC overall survival 
Overall survival (OS) was defined as time from disease diagnosis 
until death from any cause and Survival free disease (DFS) was defined 
as time from disease diagnosis until disease relapse; both were assessed 
using the Kaplan-Meier method (Figures 1 and 2). When the patients 
were divided into two groups by location-colon and rectum-no 
significant difference was found between the survival rates of the colon 
cancer group and rectal cancer group; this was assessed using the log-
rank test (Figure 3). 
Discussion 
CRC epidemiological data abounds in the worldwide literature, 
but in the case of the Portuguese population, this data is scarce and 
the existing studies are retrospective studies based in cancer registries 
but with little data that allows the characterization of the affected 
population. In the developed world, CRC represents a major public 
health problem [18]. In Portugal, it is the second most frequent cancer 
and the second cause of death by cancer [14,16] and, although CRC 
epidemiological data abounds in the worldwide literature, this data 
is scarce for the Portuguese population. The North of Portugal is 
traditionally considered to be an area of high CRC incidence. Braga 
Hospital, in the North of Portugal, has a reference area of 300,000 
patients, but no epidemiological data exists in literature. Thus, we 
designed this prospective study to characterize the patients treated 
 
Figure 1: Kaplan-Meier curves depicting overall survival CRC curve.
 
Figure 2: Kaplan-Meier curves depicting disease-free survival CRC curve.
 
Figure 3: Comparison between colon and rectum cancer survival assessed 
by log-rank test.
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at this hospital, comparing with others of high incidence population 
studies. 
Age and gender
 In this study, most of the 672 patients (419, 62.4%) were male and 
the age range of most patients (61%) was 61-80 years old. Except for 
the group older than 81 years old, CRC incidence was more frequent 
in men. Similar results to the ones of the present study were found in 
literature and the Portuguese Cancer Registry, with CRC being more 
frequent at advanced age and in men. The last results about Portuguese 
population document that CRC is more frequent in men, although 
when observing separately colon and rectal cancer, we found that colon 
cancer is slightly more frequent in women (10.6% versus 10.4%) [15]. 
Similar results were observed in epidemiological Brazilian data [19,20]. 
Advanced age is the most significant risk factor for diagnosis of CRC, 
which is defined as a disease of elderly people, with the majority of cases 
arising after 65-70 years of age and with an incidence relatively lower 
under 40 years of age. Still, 15% of cases will occur in people ≤ 50 years 
old [1,3,10,11,21-26], although another study suggests a lower value 
(7%) [27] and a large study identifies it as one of the 10 most commonly 
diagnosed cancers among men and women aged 20-49 years [26]. Early 
onset of CRC is assumed to be indicative of genetic susceptibility [22], 
often associated with a positive family history [28]. In some studies, such 
younger patients presented more advanced disease and more aggressive 
tumour grades at diagnosis and had less favourable prognosis [26-29]. 
Prevalence of advanced colorectal neoplasms increases with age and is 
higher among men than women [18,25,29-31]. Cross-sectional analyses 
estimated that men reach an equivalent prevalence at a much younger 
age than women [30]. 
Anatomic distribution of tumours
 Tumour distribution throughout colon and rectum depends on 
genetic and environmental factors involved in colorectal carcinogenesis 
and on the patient’s gender, race and age [10,29]. Several studies 
regarding CRC incidence have shown significant differences between 
colon and rectal cancer [10]. Some studies reveal that, in industrialized 
countries, CRC is more frequent in sigmoid colon and rectum [7,14]. 
Liu et al. reported a shift to the right colon in the high risk nations, for 
unknown reasons [32], and others have suggested that the frequency 
of right-sided colon cancer increases in elderly patients [10]. Our 
study revealed that colon cancer was more frequent than rectal cancer 
(65.3% versus 34.7%) and most colon cancers were left-sided (56.7% of 
all colon cancers). This data are in agreement with the world tendency 
and similar values (65.4%) were observed by Michelle Fraga Eisenhardt 
in Rio Grande do Sul (Brazil) [33]. In literature, studies have shown 
conflicting results when comparing prognosis and localization [34]. 
Reduced survival in left colon cancer compared to right colon was 
reported in a Norwegian study from 1987 and Aldrige et al. reported 
similar results [34-36], but no differences were detected in other studies 
[34,37-39]. In our study, the majority of colon cancer patients presented 
at diagnosis a localized cancer, stage IIA tumour; on the other hand, 
most rectal cancer patients were stage IV at diagnosis, supporting the 
results of the Norwegian study. 
Past personal and family history
Epidemiological studies suggest that at least 15% of colorectal 
cancers arise in individuals with an inherited predisposition for the 
disease [14,17]. The literature also reveals that positive family history 
is strongly associated with CRC [10,25]. In our study, 94.8% of the 
patients had no history of previous colorectal polyps; 4.1% had a 
previous personal history of CRC; 7.7% had a personal history of other 
cancers and 9.7% had a positive family history for CRC. Knowing 
CRC natural history, we would expect a higher incidence of previous 
colorectal polyps history. This lower value seems to result from the 
low adherence of patients to perform colonoscopy without symptoms. 
Also, the values of family history are underestimated, since a significant 
number of patients do not know their relatives’ cause of death. 
Symptoms
Symptoms of CRC can be nonspecific or quite fulminant [40]. 
Emergency situations are most commonly related to the complications 
of tumour obstruction [41] or tumour perforation [41,42]; these are 
relatively rare complications, both with a poor prognosis and high risk 
of recurrence [41]. In a meta-analysis, Jellema et al. analysed various 
symptoms of CRC and concluded that the symptoms most commonly 
investigated included abdominal pain, rectal bleeding, change in bowel 
habits, and perianal symptoms. Of the typical symptoms of CRC, only 
weight loss had some diagnostic value, with a fairly high specificity [25]. 
Most patients (81.3%) from our study were symptomatic at diagnosis. 
Analysing colon and rectal cancer, 77.4% (n=340 patients) and 88.5% 
(n=206 patients) were symptomatic at diagnosis, respectively. Digestive 
bleeding was the most frequent symptom at diagnosis for colon and 
rectal cancer (17.1% and 20%, respectively), followed by large bowel 
obstruction in colon cancer (15.0%) and digestive bleeding associated 
with change in bowel habits (17.4%) and change in bowel habits (13.2%) 
in rectal cancer. 
Macroscopic serosal involvement
Macroscopic serosal involvement corresponds to a pT3 in TNM 
classification; In our series, 69.9% of colon cancers and 53.7% of rectal 
cancer presented macroscopic serosal involvement. When macroscopic 
serosal involvement is present, even in the absence of lymph node 
involvement (AJCC/UICC stage IIB classification), it also identifies 
high-risk disease requiring adjuvant therapy [43-45]. 
Tumour differentiation
Tumour differentiation is consistently recognized as an important 
prognostic parameter [41,46]. In our series, most of the cancers 
analysed were moderated-differentiated (40.8% for colon cancer and 
39.4% for rectal cancer). Unlike some brasilian studies a higher value of 
well differentiated lesions were observed [33,47,48]. 
Vascular invasion
It was reported 54.2% and 55.6% of venous vessel invasion and 
39.3% and 44.3 of lymphatic vessels invasion, for colon and rectal cancer 
respectively. CRC exploits the lymphatic and venous drainage of the 
intestinal wall for dissemination to regional lymph nodes and distant 
organs. Vascular invasion is an adverse prognostic factor in CRC, since 
it has been demonstrated repeatedly to be an independent prognostic 
factor [43,49,50]. The diagnosis of vascular invasion in CRC specimens 
may be exceedingly difficult with conventional haematoxylin-eosin 
staining alone [51]. Literature data reported a CRC vascular invasion 
in ranges from 10% to 89% [50], most likely due to the different criteria 
used for its identification or to patient selection. Suffice it to say that in 
some studies, for instance, no distinction was made between venous 
and lymphatic vessels intramural and extramural venous invasion, or 
colonic and rectal localization of the primary tumours [43]. 
Histological staging and follow-up 
Stage at diagnosis plays a significant role in CRC survival [12,23-
25,40,52-54] and is, in fact, the main prognostic factor in CRC [1-
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3,12,23,24], but it is difficult to accurately determine the stage prior to 
surgical treatment [55]. Staging has evolved over time and, currently, 
the TNM system is used. It is an evaluation system based on 3 variables: 
primary tumour (T), regional nodes (N) and metastasis (M) [40,52]. 
In the past, patients presenting the same stage of CRC were considered 
similar in terms of prognosis. The new staging criteria recognize that 
they are usually quite different and subsets of patients with varying 
survival statistics can be found [40,55]. Less than one quarter of 
patients’ present early disease [Stage I] that is curable by surgical 
resection [12,23,40] and more than 20% of CRC patients present stage 
IV disease at diagnosis [40]. This has an impact in five year survival 
rates and we can expect a five-year survival rate greater than 90% for 
stage I [12,23,25] and less than 10% for stage IV [25]. On the other 
hand, around 40% of the patients diagnosed with CRC eventually 
develop metastatic disease [24] and about two-thirds of the patients 
undergo resection with curative intent, but 50% of the patients still die 
of the disease within five years [34,54]. As we stated above, most colon 
cancer patients from our study were stage IIA (33.7%), followed by 
stage IIIB (22.5%). Most rectal cancer patients were stage IIA (21.2%), 
followed by stage I (18.7%) and stage IV (18.2%). Despite expecting a 
worse prognosis in rectal cancer patients, we observed that 27.8% of 
colon cancer and 18.0% of rectal cancer patients died from a colorectal 
cancer-related cause. Follow-up time ranged from 2 to 7 years and, in 
that period, 14.6% of the patients with colon cancer and 19.3% of the 
patients with rectal cancer had recurrence, mostly in the liver. This data 
is consistent with literature, which shows a low percentage of patients 
diagnosed at stage I, 13.0% for colon cancer and 18.7% for rectal cancer. 
Also, the percentage of stage VI diagnosed patients was very close to 
that observed in literature, with 18.2% for rectal cancer and 18.7% for 
colon cancer. From this data, we would expect a higher mortality in 
rectal cancer patients compared to colon cancer, but we observed very 
similar results, documented by using the log-rank test when doing a 
comparison between colon and rectum cancer survival (p=0.518). 
In literature, studies have shown conflicting results when comparing 
prognosis and localization [34]. Reduced survival in left colon cancer 
compared to right colon was reported in a Norwegian study from 1987 
and Aldrige et al. reported similar results [34-36], but no differences 
were detected in other studies [34,37-39]. We also observed a lower 
value of 5 years disease recurrence-14.6% and 19.3% for colon and 
rectal cancer respectively-when compared with values of 40% found in 
literature. This data may reveal a different biological behaviour or be the 
result of the follow-up time; however, other studies with larger series 
must be done. 
Conclusions 
In the presented study, we analysed the CRC epidemiological 
characteristics of patients treated at Braga Hospital, Northern Portugal, 
in the period from January 1st 2005 to January 1st 2010. Although 
Portuguese epidemiological data are scarce, when comparing ours 
results with Brazilian and world literature data, similar results were 
observed. our study found that CRC was more often diagnosed in elderly 
and male patients and that few patients had a previous CRC personal 
or family history. Most patients were symptomatic at presentation and 
most cancers were localized in the colon, of which most was left-sided. 
Histological staging revealed that most of the colon and rectal cancers 
were stage IIA. Despite these results, we also observed that colon cancer 
patients had slightly higher mortality than rectal cancer patients (27.8% 
versus 18.0%), but a higher percentage of rectal cancer patients had 
recurrence during this period. This study on CRC is the first conducted 
in Braga, North of Portugal. This data documents the need to establish 
a nationwide CRC screening program, creating a better resource 
management and improving early diagnosis.
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